CJC-1295 (without DAC)

Overview

What is CJC-1295 (without DAC)?

CJC-1295 without DAC, also known as Modified GRF 1-29 or Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body’s natural GH secretion patterns. Unlike its DAC-modified counterpart, this version has a brief half-life of approximately 30 minutes, allowing for more precise control over growth hormone pulses and reduced risk of receptor desensitization.

Key Benefits

Preserves natural GH pulsatility, minimal side effects, no receptor desensitization, precise control over GH release

Mechanism of Action

Binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses

Pharmacokinetics

Peak: 15 min Half-life: 30 min Cleared: ~2.5 hrs

Research Indications

Natural GH Pulse Restoration

Stimulates physiological growth hormone pulses that decline with age

IGF-1 Elevation

Increases insulin-like growth factor 1 levels through enhanced GH secretion

Pituitary Function Support

Maintains healthy pituitary-somatotroph axis without suppression

Muscle Mass Preservation

Supports lean muscle maintenance through enhanced protein synthesis

Bone Density Support

May help maintain bone mineral density through GH/IGF-1 pathway

Skin Elasticity

Potential improvements in skin thickness and collagen production

Exercise Recovery

Enhances post-workout recovery through improved protein synthesis

Sleep Quality

May improve deep sleep stages when administered before bed

Injury Healing

Supports tissue repair through growth factor cascade activation

Research Protocols

Disclaimer

These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime) SubQ
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime) SubQ
Maximum GH Release 200mcg 2-3x daily with GHRP SubQ
Sleep Enhancement 100-200mcg Once at bedtime SubQ

Timing

Administer 30+ minutes away from food for optimal absorption. Morning dose upon waking, evening dose before bed for best results.

Peptide Interactions

Excellent combination - Ipamorelin (GHRP) + CJC-1295 (GHRH) provides complementary GH release through different receptor pathways
Strong synergy when combined - GHRP-6 amplifies the GH pulse initiated by CJC-1295
Potent combination for maximizing growth hormone release through dual pathway activation
Can be combined but monitor for excessive GH elevation due to Hexarelin's potency
Never combine different CJC-1295 variants - choose based on desired release pattern
Both bind to pituitary GHRH receptors. Combining saturates receptors without amplifying GH release, risking receptor desensitization and blunted pulsatility. Choose one based on your protocol goals.
Different mechanisms - MK-677 provides continuous ghrelin stimulation while CJC-1295 offers pulsatile GHRH

How to Reconstitute

Important

Always use bacteriostatic water (BAC). Sterile technique is essential.

  • 1
    Allow vial to reach room temperature (15-20 minutes)
  • 2
    Clean vial top with alcohol swab and allow to dry
  • 3
    Calculate required bacteriostatic water volume using the calculator below
  • 4
    Draw calculated volume of bacteriostatic water into syringe
  • 5
    Inject water slowly down the inside wall of the vial (never directly onto powder)
  • 6
    Gently swirl until powder completely dissolves (never shake)
  • 7
    Solution should be clear - discard if cloudy or contains particles
  • 8
    Store reconstituted solution in refrigerator at 2-8°C

Quality Indicators

  • ✓

    Legitimate source with COA

    Purchase from vendors providing certificates of analysis showing >98% purity

  • ✓

    Proper cold chain shipping

    Peptide should arrive with ice packs or refrigerated shipping in hot weather

  • ✓

    Vacuum-sealed vials

    Legitimate peptides create vacuum when reconstituted - water should be pulled in

  • !

    Check expiration dates

    Lyophilized peptide typically stable for 2 years if stored properly

  • ✗

    Pre-mixed solutions

    Avoid pre-reconstituted products - peptide degrades rapidly in solution

  • ✗

    Discolored powder

    White to off-white powder only - yellow or brown indicates degradation

What to Expect

  • Day 1-7: Improved sleep quality, vivid dreams common due to enhanced REM sleep

  • Week 2-4: Increased recovery from workouts, reduced DOMS, better pumps

  • Week 4-8: Noticeable improvements in skin quality, minor body composition changes

  • Week 8-12: More significant lean mass gains, fat loss, improved joint comfort

  • Week 12+: Continued gradual improvements in body composition and well-being

Side Effects & Safety

  • Generally well-tolerated with minimal side effects at recommended doses
  • May cause temporary facial flushing or warmth for 5-10 minutes post-injection
  • Monitor blood glucose if diabetic - GH can affect insulin sensitivity
  • Not recommended for those with active cancer due to growth-promoting effects
  • Avoid if you have diabetic retinopathy or severe kidney disease
  • Persistent joint pain or carpal tunnel symptoms (indicates excessive GH)
  • Significant water retention or edema lasting more than 2 weeks
  • Unexplained headaches or vision changes
  • Extreme fatigue or lethargy (may indicate cortisol suppression)
  • Any signs of allergic reaction at injection sites

References

Long-term Safety Profile of Modified GRF Analogs (2015)

Animal model | 6 months | Daily administration

No significant adverse effects on pituitary morphology or function with chronic use, supporting the safety of long-term pulsatile GHRH analog administration.

Comparative Analysis: CJC-1295 vs Native GHRH (2010)

In vitro + Human | Various doses | Receptor binding assays

Found CJC-1295 without DAC had 4x greater receptor affinity than native GHRH and enhanced resistance to enzymatic degradation, explaining its superior efficacy.

Growth Hormone Pulsatility with Mod GRF 1-29 (2008)

Human | 100mcg 3x daily | 30 days | 24 subjects

Showed preservation of natural GH pulsatility patterns when administered 3 times daily, with no evidence of pituitary desensitization over the study period.

Pharmacokinetics of Modified GRF(1-29) in Healthy Adults (2006)

Human | 100-200mcg | Single dose | 12 subjects

Demonstrated rapid absorption with peak GH levels at 15-30 minutes post-injection, establishing the short half-life profile and optimal dosing frequency for pulsatile GH release.